Compare FTCI & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTCI | WHWK |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.0M | 95.2M |
| IPO Year | 2021 | N/A |
| Metric | FTCI | WHWK |
|---|---|---|
| Price | $11.87 | $2.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $11.50 | $7.00 |
| AVG Volume (30 Days) | 87.4K | ★ 137.0K |
| Earning Date | 11-12-2025 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $80,028,000.00 | $14,384,000.00 |
| Revenue This Year | $113.41 | N/A |
| Revenue Next Year | $106.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.53 | N/A |
| 52 Week Low | $2.13 | $1.39 |
| 52 Week High | $12.70 | $3.81 |
| Indicator | FTCI | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 58.47 | 58.29 |
| Support Level | $11.52 | $2.36 |
| Resistance Level | $12.70 | $2.77 |
| Average True Range (ATR) | 0.84 | 0.16 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 68.21 | 61.22 |
FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.